HEALTH SCIENCES ACQUISITIONS CORP 2 HSAQ 深 沪
已收盘 01-26 16:00:00 美东时间
13.31
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 13.31
- 总市值 14.92万
- 52周最高 13.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.41
- 委 比 0.00%
- 总股本 1.12万
- 历史最高 14.66
- 量 比 0
- 振 幅 0.00%
- 历史最低 9.41
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Novo Nordisk Says Wegovy Showed An Average 22.6% Weight Loss For Premenopausal Women With Obesity, With More Than 41% Achieving 25% Or More Weight Loss
Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing that the higher dose of the weight loss drug
05-12 18:34
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Market-Moving News for May 1st
AAPL: 4% | Apple shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, announced a $100 billion share buyback, and raised its
05-01 19:16
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Eton Pharmaceuticals has relaunched HEMANGEOL, the only FDA-approved treatment for infantile hemangioma, a rare pediatric disease. Now exclusively available through Anovo Specialty Pharmacy, HEMANGEOL aims to streamline access and therapy initiation. Eton has integrated its Eton Cares patient support program, offering $0 co-pay for eligible patients and expanded assistance programs. Infantile hemangiomas are fast-evolving, making timely intervent...
05-01 10:50
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Emergent BioSolutions (NYSE:EBS) held its first-quarter earnings conference cal...
05-01 05:54
Emergent BioSolutions Receives Singapore's Health Sciences Authority Approval For Expanded Indication For ACAM2000
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include
04-30 19:58
Singapore HSA approves Emergent ACAM2000 vaccine label expansion to include mpox
Singapore HSA approves Emergent ACAM2000 vaccine label expansion to include mpox Singapore Health Sciences Authority cleared expanded indication for Emergent BioSolutions ACAM2000 to cover mpox prevention in high-risk adults. Decision widens Singapore authorization beyond smallpox, supporting outbre
04-30 19:55
Cognizant targets 16%-16.2% adjusted operating margin in 2026 through Project Leap
Earnings Call Insights: Cognizant (CTSH) Q1 2026 Management view "We delivered a solid first quarter with revenue growth in the upper half of our guidance range, expanded adjusted operating margin and...
04-30 01:02
